Paper. Jungwirth J, Westenhöfer S, Aicher HD et al.. The Lancet Regional Health. Europe, 1 Jun 2026.
Tags: Observational, Psilocybin, Depression.
Switzerland allows limited medical use of psilocybin. Records from 19 treatment-resistant patients at the Psychiatric University Hospital Zurich, given one to four sessions, show depression scores falling from 31 to 20 on average. 33% responded and 22% reached remission, with no serious adverse events.
How much weight it carries: Retrospective, uncontrolled and small, and patients stayed on other medication. Response rates are below those in controlled trials. (Humans, n = 19, Retrospective, Peer reviewed)